Salute e Benessere

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research &…

"Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials. "His exceptional experience, coupled with our cutting-edge platform, puts us in the position to further enhance our impact on the pharmaceutical sector, hyper-accelerating the development of new drugs with high efficiency and cost-effectiveness." "Daniel's appointment is a testament to our commitment to…
PR Newswire
12/02/2024

On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to…

As Noul's malaria diagnostic solution, miLab™ MAL was introduced as 'an innovative product that will enter scale-up level' in Unitaid's 2022 Annual Report, it is getting attention from the international community as an innovative malaria diagnostic solution that overcomes the limitation of rapid diagnostic testing and manual microscopic diagnosis. According to the results of a clinical study of a total of 1,649 patients in Ethiopia and Ghana, unveiled in October 2023 at the American Academy of…
PR Newswire
12/02/2024

Orexo and Sobi agree to advance feasibility study with AmorphOX

Nikolaj Sørensen, President and CEO of Orexo, said, "Sobi is a leading biopharmaceutical company, and we are pleased to see how the unique properties of AmorphOX can be successfully applied to one of Sobi's biomolecules. Advancing the collaboration is another proof of concept for AmorphOX and with the combined expertise of the companies I am certain we can learn more about the value potential for our scalable drug delivery platform. The collaboration is still in an early development stage…
PR Newswire
12/02/2024

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing…

These tests can be used for both assessing the anti-Xa activity of heparin therapy as well as the three authorised Factor Xa inhibitors. This will bring standardisation and automate the reconstitution process without lab user intervention, saving time for other activities. The tests can be run on indicated cobas® t analysers and benefit from Roche's Anti-Xa innovative cassette technology. The reagent cassette concept ensures high quality of results by reducing risk of contamination and…
PR Newswire
12/02/2024

Polaroid Therapeutics completes pre-clinical milestones in the development of…

Today, the misuse and overuse of antimicrobials are the main drivers of AMR. When antibiotics and antimicrobial agents are used excessively or inappropriately, bacteria, viruses, fungi, and parasites can adapt to them, making these treatments less effective over time. According to the World Health Organization, AMR is one of the top global public health and development threats. It is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to…
PR Newswire
12/02/2024

BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT

The Company will pay a finder's fee of $16,976 in cash related to the final tranche of the financing. The Company will pay a finder's fee of$16,976in cash related to the final tranche of the financing. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( www.biovaxys.com ), a biopharmaceuticals company based inVancouver, Canada, is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for...
PR Newswire
10/02/2024

BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for working capital purposes. The private placement is subject to the approval of the Canadian Securities Exchange. The Company will pay a finder's fee of$57,400in cash related to the financing. The Company anticipates closing the second and final tranche of the...
PR Newswire
10/02/2024

New Late Breaking Preliminary Data Demonstrate Balt's Squid™ Liquid Embolic May…

Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma during the late-breaking session at the International Stroke Conference in Phoenix, AZ. The preliminary data demonstrates that rates of complications thus far are low and embolizing the MMA for the treatment of Chronic Subdural Hematoma (cSDH) potentially improves the success rates of both surgical and non-surgical treatments. Co-Principal Investigator Adam...
Nasdaq GlobeNewswire
09/02/2024

Ambu A/S: Reporting of transactions made by persons discharging managerial…

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S's shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Attachment 09_02_2024 Henrik Skak Bender
Nasdaq GlobeNewswire
09/02/2024

Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.The below transactions concern allocation of share options.For further details, reference is made to Coloplast's Remuneration Policy. The policy is available on the group website at this address:...
Nasdaq GlobeNewswire
09/02/2024

Wearable Injectors Market Worth $15.1 Billion | MarketsandMarkets™

The steady rhythm of chronic illnesses like diabetes, autoimmune disorders, and pain management pulsates across continents. These vast, unmet needs create a fertile landscape for innovation, and wearable injectors, with their precise dosing and user-friendly features, harmonize perfectly with the demand for convenience and adherence. A vibrant melody of research and development amplifies the market's tempo. Leading manufacturers collaborate with universities and research institutions, composing…
PR Newswire
09/02/2024

Coloplast Finance B.V. - Interim Financial Report, Q1 2023/24

Q1 2023/24 Interim financial results, Q1 2023/241 October 2023 - 31 December 2023Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies.Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and...
Nasdaq GlobeNewswire
09/02/2024

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-masked Phase 2 clinical trial and is planned to begin in 2Q 2024NCP is an Orphan disease as listed in the National Organization for Rare Disorders LONDON and NEW YORK, Feb.09, 2024(GLOBE...
Nasdaq GlobeNewswire
09/02/2024

Vistin Pharma ASA: Invitation to Q4 2023 conference call

Vistin Pharma ASA will release its fourth quarter and preliminary 2023 results on Friday 16 thof February 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 16 thof February at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The fourth quarter conference call will be available via web and audio through the following access points: Webcast: ...
Nasdaq GlobeNewswire
09/02/2024

Invitation to an extraordinary shareholders' meeting of Novozymes A/S

An extraordinary shareholders' meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark. Attachments 2024_09_EGM_InvitationNotice convening the extraordinary general meeting 2024Invitation til ekstraordinær generalforsamling 2024
Nasdaq GlobeNewswire
09/02/2024

MCAN Health Announces Sponsorship to UK National Pharmacy Association, in line…

Esteemed UK Prime Minister Rishi Sunak, who worked in his mother's pharmacy during his youth, also shows his support to the NPA and recognizes the indispensable role of local pharmacies. Sunak, having personally witnessed the invaluable contributions of these pharmacies to the health of the UK community, emphasizes the need to empower individuals to access care services conveniently at local pharmacies, thereby reducing the strain on GP waiting lists. Esteemed UK Prime MinisterRishi Sunak,...
PR Newswire
09/02/2024

MAXIMA GRUPĖ receives SBTi validation for its greenhouse gas emissions reduction…

MAXIMA GRUPĖ, which operates retail chains and e-commerce in the Baltic States, Poland, and Bulgaria, has its near-term science-based emissions reduction targets validated by the Science Based Targets initiative (SBTi) at the end of December 2023, after committing to set such targets earlier in March the same year. The Scope 1 and 2 targets ambition have been classified as in line with 1.5 o C trajectory. As of 8 February 2024, MAXIMA GRUPĖ has been officially included on the SBTi list of...
Nasdaq GlobeNewswire
09/02/2024

Dedicare's Year-end Report 1 January - 31 December 2023: Continued growth and…

The period January - December 2023 The period January -December 2023 Performance measures Dividend Dedicare's Board of Directors has proposed an ordinary dividend ofSEK 6.50per share (6.00), corresponding toSEK 62.2 million(57.4) for the financial year 2023. The group's dividend policy is that the annual dividend should amount to at least 50 percent of consolidated net profit. The proposed dividend corresponds to 56.3 percent (56.6) of net profit for the year...
PR Newswire
09/02/2024

Medicover: Year-end report January-December 2023

Full year Full year REVENUE AND EARNINGS Definition and reconciliation of alternative performance measures are available atwww.medicover.com/financial-information.1) 2022 is restated for IFRS 17Insurance contracts. For further information, refer to note 1. CEO Statement I am pleased to look back at another year of strong growth. InFebruary 2023, we announced new, even more ambitious growth targets for the next three-year period, and so far, we have delivered on our...
PR Newswire
09/02/2024

Invitation to presentation of Mendus' year-end report for 2023

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session. Listen to the presentation webcast:https://ir.financialhearings.com/mendus-q4-2023Please send any questions ahead of the presentation to...
Nasdaq GlobeNewswire
09/02/2024

Coloplast launches Peristeen® Light for people with bowel disorders

The new transanal irrigation device is designed to help people facing defecation issues or stool leakage.It is estimated that 10-15% of the world's population are affected by chronic constipation 1 and that 6% struggle with faecal incontinence 2, both of which can cause physical discomfort and mental distress 3. Although transanal irrigation treatment can help, the journey to treatment is often challenging with many patients left untreated. For some patients, symptoms are not...
Nasdaq GlobeNewswire
09/02/2024

Coloplast A/S - Interim Financial Report, Q1 2023/24

Q1 2023/24 Interim financial results, Q1 2023/241 October 2023 - 31 December 2023Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1)of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies.Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 9% (Advanced Wound Dressings 9%) and...
Nasdaq GlobeNewswire
09/02/2024

KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating…

The initiation report was published February 8, 2024. KBC joins three other banks whose research analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price. “KBC Securities' initiation of coverage reflects strong confidence in our ability to achieve this year's milestones, which include the planned commercialization of our ARC-EX ®platform later this year,” said Dave Marver, CEO of ONWARD Medical. “The KBC...
Nasdaq GlobeNewswire
09/02/2024

IBA acquires Radcal Corporation to expand Medical Imaging Quality Assurance…

Highly complementary acquisition continues IBA's expansion strategy to lead the Radiotherapy, Medical Imaging Dosimetry and Quality Assurance markets globallyLouvain-la-Neuve, Belgium, February 9, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, announced today it has signed an agreement to acquire all the assets of Radcal Corporation, a leader in...
Nasdaq GlobeNewswire
09/02/2024
Altri  Comunicati